C. L. Corless - Concepedia

Concepedia

Author

C. L. Corless

Oregon Health & Science University

Also Known As

C Corless, C L Corless, C. Corless, C. L. Corless, C.L. Corless, Chris Corless, Chris L. Corless, Christopher L. Corless, Kyoo Choi

35

Publications

1.1K

Citations

10

H-Index

40

Concepts

All Affiliations

Oregon Health & Science University Dana-Farber Cancer Institute Novartis (Switzerland)Stanford University Massachusetts General Hospital

CL

About

C. L. Corless is an author at Oregon Health & Science University specializing in medicine, health sciences, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.1K
2	Health Sciences	6	6	586
3	Gastroenterology	3	3	328
4	Cellular Physiology	1	1	166
5	Endocrinology	1	1	23

C. L. Corless

×

10

Publications

1.1K

Citations

10

H-Index

	Year	Citations
MicroRNA expression signature of human sarcomas Subbaya Subramanian, Weng‐Onn Lui, C-H Lee, Oncogene Microrna Expression SignaturePathologySmall RnaMicrorna DetectionMedicine	2007	228
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. George D. Demetri, Robert S. Benjamin, Charles D. Blanke, PubMed Surgical OncologyNew TechnologiesGastroenterologyPathologyOptimal Management	2004	175
Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells Robert W. O’Rourke, Ashley E. White, Monja D. Metcalf, Diabetologia ObesityInflammationMetabolic SyndromeMedicinePhysiology	2011	166
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy Eytan Ben‐Ami, Constance M. Barysauskas, Margaret von Mehren, Annals of Oncology OncologyGastrointestinal OncologyMedicineLong-term Follow-up ResultsClinical Trials	2016	160
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial Daniel J. DeAngelo, Tracy I. George, Andrea Linder, Leukemia Phase Ii TrialAdvanced Systemic MastocytosisSystemic TreatmentMast Cell DisorderImmunology	2017	136
Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study Regine Schneider‐Stock, Carsten Boltze, Jerzy Lasota, Clinical Cancer Research P16 LossImmunologyGastroenterologyPathologyGastric Tumors	2005	119
Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate Charles D. Blanke, George D. Demetri, Margaret von Mehren, Journal of Clinical Oncology Cancer ManagementGastroenterologyPathologyOncologyPhase Ii	2006	34
A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). Suzanne George, Margaret von Mehren, Michael C. Heinrich, Journal of Clinical Oncology OncologyGastrointestinal OncologyEligible PtsMedicineHand-foot Skin Reaction	2011	28
Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients D. Elizabeth Le, Daniel L. Marks, E.A. Lyle, Surgical Endoscopy ObesityMetabolic SyndromeBariatric SurgeryClinical PredictorsHepatology	2007	23
The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial. Jason Gotlib, Tracy I. George, C. L. Corless, Blood	2007	21

Page 1